TELIX PHARMACEUTICALS LIMITED (TLX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

TLX

TLX - TELIX PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 6.45
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$14.36

14 Oct
2025

-0.120

OPEN

$14.56

-0.83%

HIGH

$14.79

1,627,198

LOW

$14.36

TARGET
$27.20

-1.20 change from previous day

 89.4% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
TLX: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) - 1.9 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx15.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx783.2 M
Book Value Per Share xxxxxxxxxxxxxxx169.8
Net Operating Cash Flow xxxxxxxxxxxxxxx43.0 M
Net Profit Margin xxxxxxxxxxxxxxx6.37 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx13.92 %
Return on Invested Capital xxxxxxxxxxxxxxx7.72 %
Return on Assets xxxxxxxxxxxxxxx5.18 %
Return on Equity xxxxxxxxxxxxxxx13.92 %
Return on Total Capital xxxxxxxxxxxxxxx12.46 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx14.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx21 M
Long Term Debt xxxxxxxxxxxxxxx560 M
Total Debt xxxxxxxxxxxxxxx581 M
Goodwill - Gross xxxxxxxxxxxxxxx107 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx710 M
Price To Book Value xxxxxxxxxxxxxxx14.50

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx48.5 M
Capex % of Sales xxxxxxxxxxxxxxx6.19 %
Cost of Goods Sold xxxxxxxxxxxxxxx273 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx428 M
Research & Development xxxxxxxxxxxxxxx195 M
Investments - Total xxxxxxxxxxxxxxx56 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

1

xxx, xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

15/10/2025

1

Overweight

$25.40

76.88%

Management at Telix Pharmaceuticals has upgraded FY25 revenue guidance to US$800-820m from US$770-800m, above Morgan Stanley's forecast of US$782m and consensus of US$799m.

The broker notes PSMA imaging revenue of US$155m in 3Q25 was broadly steady quarter-on-quarter, supported by 3% volume growth and a 2% price decline.

It's noted the Illuccix label has been expanded to include patient selection for radioligand therapy in the pre-chemotherapy setting.

Morgan Stanley lifts its FY25 revenue forecast to US$809m but assumes most of the uplift is reinvested in R&D.

The broker's target price edges down to $25.40 from $25.60, and an Overweight rating is retained. Industry View: In-Line.

FORECAST
Morgan Stanley forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.00 cents.
Morgan Stanley forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.55 cents.

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

29/09/2025

1

Buy

$28.13

95.89%

Telix Pharmaceuticals has received transitional pass-through (TPT) status for its second-generation prostate cancer diagnostic Gozellix, offsetting the loss of TPT for Illuccix from June 30, 2025, notes Jarden.

The analysts highlight the decision underpins Telix’s two-product strategy and secures reimbursement for 2-3 years. The recent share price retreat is seen as excessive.

No earnings revisions are made by the broker as TPT approval was assumed. Gozellix has a longer shelf life, enabling greater distribution, and is expected to ramp sales quickly.

Jarden maintains a Buy rating and $28.13 target price.

FORECAST
Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.87 cents.
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 16.02 cents.
Access Extra Coverage Research History >

TLX STOCK CHART

FNArena News on TLX

1
In Brief: Telix, Santos, Woodside & Acusensus

Oct 10 2025 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Oct 07, 2025

Oct 07 2025 - Daily Market Reports
3
Rudi’s View: Amcor, Generation Development, Life360, Redox, Worley & More

Oct 02 2025 - Rudi's View
4
Australian Broker Call *Extra* Edition – Sep 29, 2025

Sep 29 2025 - Daily Market Reports
5
Next Week At A Glance – 29 Sep – 3 Oct 2025

Sep 26 2025 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
2
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
3
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
4
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
5
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
6
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
7
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
8
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
9
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
10
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia